Webinar: Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery
Our webinar “Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery” was live on June 22, 2022 at 1PM EDT.
In this webinar, we
- Introduced Biocytogen’s highly immunodeficient B-NDG mouse model
- Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models
- Described how B-NDG models recapitulate critical aspects of human biology, making them a powerful tool for biomedical research
About the Speaker & Panelists
John Charpentier, Ph.D, Business Development Manager, Biocytogen Boston
A native of New England, John spent nearly a decade in laboratories focused on questions of fundamental T cell biology. After earning a Ph.D. in immunology from the University of Michigan, he returned home to Boston in July 2021 to join Biocytogen as a Business Development Manager. In this role he liaises between Biocytogen’s clients and scientific teams to ensure collaboration success.
Rebecca Soto, Ph.D. Scientific Content Specialist, Biocytogen Boston
Rebecca recently completed her Ph.D. in Biological and Biomedical Sciences from Harvard University. Using various animal models, her thesis work primarily focused on epigenetic regulation of developmental hematopoiesis. At Biocytogen, Rebecca provides scientists with the information they need to further their research goals.
James Jin, Ph.D, Vice President, Biocytogen
Dr. James Jin received his Ph.D. in virology at Wuhan University in 1997. He received postdoctoral training at Colorado State University, and worked as a research assistant professor at the University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a senior scientist. Dr. Jin joined Biocytogen as the Director of Technology in 2011, and was promoted to Vice President in 2012. His research experience spans the fields of virology, immunology, proteomics, protein structure, human stem cells, and genetic targeting of animal models.